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http://dx.doi.org/10.1016/j.fjs.2013.Summary Tumoral calcinosis (TC) is a rare neoplasm-like condition that can be sporadic, fa-
milial, or secondary to other diseases. The treatment of different types of TC may differ based
on the etiology. In certain situations such as intolerable pain due to involvement of local tis-
sue, repeated skin ulceration, or fistula formation, surgical excision is unavoidable. This case
report aims to share the rare condition. A brief review is also presented, including the patho-
genesis and current management strategies of TC. We report a rare case of TC secondary to
end-stage renal disease in a 65-year-old female patient presenting with a huge, painful,
buttock area tumor involving the sacrum that required extensive surgical excision and gluteus
maximus myocutaneous flap reconstruction. Complete resolution was achieved after a wide
surgical excision followed by local flap reconstruction and medical control. Surgical excision
alone may result in a high recurrence rate when TC is secondary to other diseases. Combina-
tion with medical treatment to achieve phosphate deprivation is more effective.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Tumoral calcinosis (TC) is a rare clinical condition that can
be primary (sporadic or familial) or secondary to other
diseases, particularly end-stage renal disease (ESRD).clare no conflicts of interest.
lastic Surgery, Department of
ang Gung Memorial Hospital,
yahoo.com.tw (C.-H. Chen).
ight ª 2013, Taiwan Surgical Asso
06.010Although different types of TC do not differ in their radio-
logic and histopathologic presentations, the treatment may
differ based on etiology. TC (also known as Teutschla¨nder
disease, calcifying bursitis, lipocalcino-granulomatosis,
calcifying collagenolysis, and Kikuyu bursa) is a deposition
of calcium phosphate and calcium hydroxyapatite within
periarticular soft tissues.1 Differential diagnoses of soft-
tissue calcification include mixed connective tissue dis-
eases, dermatomyositis, calcinosis circumscripta, calcific
tendinitis or calcific bursitis, and heterotrophic calcifica-
tion. Neoplastic diseases such as parosteal osteosarcoma,
chondrosarcoma, and synovial sarcoma should also beciation. Published by Elsevier Taiwan LLC. All rights reserved.
24 Y.-P. Lin, C.-H. Chenconsidered.2 Surgical resection of the calcified mass is the
main treatment for primary TC, but for hemodialysis-
related secondary TC, phosphate lowering measures may
be considered first.3
However, in certain situations such as intolerable pain
due to involvement of local tissue, repeated skin ulcera-
tion, or fistula formation, surgical excision is unavoidable.4
Here we present a case of huge lumbosacral area TC sec-
ondary to ESRD that required surgical excision and imme-
diate flap reconstruction for defect management.
2. Case report
A 65-year-old female patient presented at the outpatient
department (OPD) with a 1-year history of a progressive,
enlarging mass over her right buttock area. The mass was
firm, freely moveable, severe-tender, with irregular bor-
ders, and had protruded out of the skin (Fig. 1). The patient
medical history included significant underlying conditions
such as ESRD under regular hemodialysis for 10 years and
congestive heart failure. The mass was initially noted
approximately 2 years previously by the patient as a small,
painful nodule with slight progression in size. She sought
initial medical attention 1 year previously at the general
surgery OPD. An abscess was initially suspected, and a small
amount of whitish discharge was found after incision and
drainage under local anesthesia. Follow-up computed to-
mography (Fig. 2) showed a solid calcified mass over the
subcutaneous area of the right buttock, 34 mm in diameter,
which was not connected with the underlying muscle or
bone. Although total excision under general anesthesia was
suggested, the operation was cancelled due to unfavorable
heart ejection fraction of this patient. However, the nodule
gradually enlarged and became a firm tumor, so the patient
was transferred to the Plastic and Reconstructive Surgery
OPD. Repeat episodes of skin erosion in the overlying region
was noticed during OPD follow up, and finally skin breakage
occurred with a visible 5 cm  8 cm, multilobular yellowish
mass protruding through the skin. She complained of local
pain and, due to the severe interference to her dailyFigure 1 Initial presentation of the protruding tumor at our
outpatient department. The tumor was attached to the supe-
rior medial pole of the right buttock area.activities, excision of the tumor with local flap recon-
struction was arranged.
Reviewing her family history, there was no similar con-
dition within the family. No unknown fever or weakness had
occurred during this period of time, and there were no
generalized, systemic complaints. The biochemistry results
of blood sampling (Table 1) revealed hypercalcemia in
previous examinations (calcium Z 10.7 mg/dl 2 years pre-
viously, 11.4 mg/dl 1 year previously; reference range,
9e10.5 mg/dl) and normocalcemia (calcium Z 9.9 mg/dl)
just prior to the operation. In addition, hyperphosphatemia
(phosphorousZ 6.97 mg/dl; reference range, 2.4e4.1 mg/
dl) and hyperparathyroidism (intact parathyroid
hormone Z 2270 pg/ml; reference range, 10e55 pg/ml)
was found. Uric acid was also checked and was within
normal limits (6.7 mg/dL).
An operation was performed for total excision of the
tumor, which extended 5 cm into the skin. The resulting
huge soft tissue defect and sacral bone exposure was too
large for primary closure (Fig. 3). Hence, a right gluteus
maximus myocutaneous flap was rotated to obliterate the
dead space and reconstruct the soft tissue defect. Grossly,
an ill-defined and firm subcutaneous tumor with yellow-
ewhite calcareous material was noted, weight 143 g and
7.8 cm  6.8 cm  6 cm in size (Fig. 4). Pathology
demonstrated amorphous calcified material surrounded by
granulomatous reaction and fibrous tissue (Fig. 5). A TC was
diagnosed. After the operation, continuous low phosphate
diet and oral medication with phosphate binding antacid
was prescribed (aluminum/magnesium hydroxide three
times a day during a meal) and no local recurrence was
noted at the 1-year follow-up (Fig. 6). The patient was
capable of sitting and lying down without any discomfort
and had good functional recovery.Figure 2 Computed tomography scan prior to the operation
showed a solid calcified mass over the subcutaneous area of
the right buttock, 34 mm in diameter, which was not connected
with the underlying muscle or bone.
Table 1 The biochemistry results of blood sampling. Abnormal data outlined in bold face.
(Normal range) 2009/04/13 2010/09/17 2011/03/16 2012/05/29 2012/06/07
BUN, mg/dl (6e21) 45.3 25.5
Cr, mg/dl (M: 0.64e1.27, F:0.44e1.03) 6.82 7.58 4.41
Na, mEq/L (135e147) 144 140
K, mEq/L (3.6e5.0) 5 3.6
Ca, mg/dl (9e10.5) 10.7 11.4 9.9 9.3
P, mg/dl (2.4e4.1) 6.9 6.1 6.9 6.1
Uric acid, mg/dl (M: <7.0, F< 6.0) 6.8 6.1 6.7
iPTH, pg/ml (10e55) 2270
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TC is a rare, benign lesion that was first named by Inclan
et al5 in 1943. TC is characterized by tumor-like deposits of
calcium, which are usually in periarticular regions. The
joints are usually spared, and lesions may be multiple. The
tumor itself is usually painless, although mass effects
ranging from local pain caused by neural involvement to
functional impairments may also be present.3 TC can be
classified into three clinical types based on pathogenesis:
(1) primary normophosphatemic TC (sporadic); (2) primary
hyperphosphatemic TC (familial); and (3) secondary TC.6
The first type affects young patients (without any familial
history) and is usually a single lesion with low chance of
recurrence after excision. The second type is hereditary
and is a metabolic disease with decreased fractional
phosphate excretion and increased 1,25-dihydroxyl-vitamin
D synthesis.7 It affects multiple sites including teeth, ves-
sels, diaphysis, and cranium, and recurrence is common.
The third type derives from systemic diseases that promote
ectopic calcification such as hyperparathyroidism and
sarcoidosis.8 Secondary hyperparathyroidism due to poor
blood phosphate level control in an ESRD patient, just like
this patient, is the primary cause in third type patients.
For end-stage renal failure patients, secondary hyper-
parathyroidism followed by hyperphosphatemia is notFigure 3 Huge, deep defect (10 cm  7 cm  5 cm) with
sacral bone exposure after total tumor excision. The broken
lines depict the internal borders of the defect.uncommon. According to the 2012 United States Renal Data
System Annual Data Report, the prevalence of ESRD pa-
tients in Taiwan is highest in the world, at 2584 per million
population. Additionally, improving dialysis care quality
and National Health Insurance coverage has led to better
survival rates for these patients.9 Hence, although the
incidence of TC in this patient cohort is still unclear, sur-
geons should be aware of potentially increasing pre-
sentations of this disease, and become familiar with the
pathogenesis and treatments associated. Due to the benign
presentation of the mass, TC is often misdiagnosed by
inexperienced surgeons, resulting in incomplete excision
and disease recurrence.
Pathogenically, TC is a result of two concurrent events:
(1) trauma that initiates a multistepped reaction to injury
in soft tissues and skin; and (2) a multifactorial elevation of
the serum calcium phosphate product principally caused by
hyperphosphatemia. The pathologic lesion is specific,
exhibiting features distinguishable from other calcifying
entities, but is similar pathologically for all three TC types.
In general, pathology characteristics demonstrate a foreign
body granulomatous reaction with infiltrations by giant
cells and lymphocytes.10
This response is inaugurated by histiocytes and their
derivatives, synovial intimal cells and dysmorphic osteo-
clasts.11 The histiocytes aggregate, phagocytize lipids, andFigure 4 Firm subcutaneous tumor with yellowewhite
calcareous material inside.
Figure 6 (A) One-year postoperative image of the reconstructed
spine. No recurrence of the calcifying lesion is noted.
Figure 5 (A) Pathology report shows necrotic histiocytes
with calcification surrounded by granulation reaction and
lobular fibrous septum. (B) Locule created by and filled with
necrotic histiocytes. The cavity is lined by mononuclear cells
forming a bursa-like structure (black arrow: giant cells; white
arrowheads: calcium deposits).
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process occurs.
Treatments for TC include surgery, phosphate depriva-
tion, or a combination of both. Surgery is recommended for
patients with functional impairment, pain, or skin erosion.4
Complete excision is effective for early primary normo-
phosphatemic TC, and has a low recurrence rate. However,
the recurrence rates are higher for the other two types, and
are an important concern for the surgeon for proper sur-
gical management. In addition, recurrent masses are more
likely to be progressive, particularly for incompletely
excised lesions. In cases that require wide excision resulting
in large tissue defects, flaps or other reconstructive mea-
sures may become necessary.6 For the present case, the
large mass with skin breakage resulted in local pain and
severe functional impairment, requiring reconstruction
with gluteal maximus rotational flap after excision. To our
knowledge, TC cases requiring the use of flaps to cover the
defect are rarely report in the literature.
Medically, phosphate lowering interventions are also
important in the management of TC in ESRD or patients
with chronic renal failure, because calcium and phosphorus
metabolism abnormalities are common in this cohort.12
Methods to decrease phosphate concentration include a
low calcium and phosphate diet plus use of phosphate
binding antacid, e.g., aluminum/magnesium hydroxide.
Other methods such as large oral doses of calcium or
vitamin D sterols may aggravate hypercalcemia and
hyperphosphatemia, and can be unsuitable for patients
with calcifying lesions.13 Parathyroidectomy to control hy-
percalcemia and hyperphosphatemia may also be per-
formed, with reports of TC regression after subtotal
parathyroidectomy, although this procedure may be
controversial.3,14 For our case, due to the occurrence of
skin breakage and large size of the tumor, primary excision
was performed with local reconstruction, and the patient
refused further intervention on the parathyroid glands.
Otherwise, complete resolution of the lesion has been re-
ported through medical management alone.15 For TCarea of the right buttock. (B) Lateral view of the lumbosacral
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ported after renal transplantation.16 Currently the most
effective treatment is believed to be a combination of
surgical excision and medical management, including
phosphate deprivation therapy or long-term use of acet-
azolamide.17 Therefore, our patient was treated with sur-
gical management due to the size and interference with
common daily activities of the TC lesion, and further
management with phosphate-binding antacid and consul-
tation with her nephrologist.
In conclusion, TC is a rare condition, and large cases
requiring flap reconstruction are seldom reported in the
literature. For TC secondary to other medical condition,
such as ESRD, surgical resection with clear margins com-
bined with medical control to achieve phosphate depriva-
tion is the most effective strategy. As a plastic surgeon,
knowledge of this rare condition is critical prior to surgical
excision and reconstruction to prevent recurrence.
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